Signet Investment Advisory Group Inc. Has $4.42 Million Position in Johnson & Johnson $JNJ

Signet Investment Advisory Group Inc. boosted its position in Johnson & Johnson (NYSE:JNJ) by 0.6% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 28,922 shares of the company’s stock after purchasing an additional 170 shares during the period. Johnson & Johnson accounts for about 2.3% of Signet Investment Advisory Group Inc.’s portfolio, making the stock its 17th biggest holding. Signet Investment Advisory Group Inc.’s holdings in Johnson & Johnson were worth $4,418,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. GFG Capital LLC acquired a new position in Johnson & Johnson in the 2nd quarter worth about $35,000. Stone House Investment Management LLC acquired a new position in Johnson & Johnson in the 1st quarter worth about $47,000. 1248 Management LLC acquired a new position in Johnson & Johnson in the 1st quarter worth about $48,000. von Borstel & Associates Inc. acquired a new position in Johnson & Johnson in the 1st quarter worth about $49,000. Finally, Harvest Fund Management Co. Ltd acquired a new position in Johnson & Johnson in the 1st quarter worth about $52,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on JNJ shares. JPMorgan Chase & Co. upped their target price on Johnson & Johnson from $185.00 to $200.00 and gave the stock a “neutral” rating in a report on Tuesday, September 16th. Bank of America increased their price target on Johnson & Johnson from $198.00 to $204.00 and gave the company a “neutral” rating in a research note on Wednesday, October 15th. Morgan Stanley set a $190.00 price target on Johnson & Johnson in a research note on Wednesday, October 15th. Sanford C. Bernstein increased their price target on Johnson & Johnson from $172.00 to $193.00 and gave the company a “market perform” rating in a research note on Monday, October 6th. Finally, Johnson Rice set a $190.00 price target on Johnson & Johnson and gave the company a “hold” rating in a research note on Wednesday, October 22nd. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and a consensus price target of $199.05.

Johnson & Johnson Trading Down 0.0%

NYSE JNJ opened at $190.31 on Tuesday. The business has a 50 day simple moving average of $182.54 and a 200 day simple moving average of $166.65. Johnson & Johnson has a one year low of $140.68 and a one year high of $194.48. The stock has a market capitalization of $458.50 billion, a P/E ratio of 18.37, a P/E/G ratio of 2.24 and a beta of 0.40. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.07 and a quick ratio of 0.80.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%.The business had revenue of $24.02 billion during the quarter. Research analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be paid a dividend of $1.30 per share. The ex-dividend date of this dividend is Tuesday, November 25th. This represents a $5.20 annualized dividend and a yield of 2.7%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 50.19%.

Insider Buying and Selling

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the firm’s stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the sale, the executive vice president owned 178,013 shares of the company’s stock, valued at $31,652,491.53. This trade represents a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 0.16% of the stock is owned by corporate insiders.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.